Loading patent…
AssigneeThe Johns Hopkins University
InventorsMichael Lim, Christopher Jackson, Ayush Pant, Henry Brem
Estimating the term…
The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods utilizing Meteorin-like (METRNL), C-X-C Motif Chemokine Receptor 6 (CXCR6) and/or endogenous C-X-C Motif Ligand 16 (CXCL16) as immune-oncology targets. Accordingly, in one aspect, the present invention provides compositions and methods directed to the knockout of METRNL, CXCR6 and/or CXCL16 expression in a cell. In particular embodiments, the cell is a T cell. In a specific embodiment, the present invention provides an engineered T-cell comprising disruption in the METRNL, CXCR6 and/or CXCL16 gene sequence. In another embodiment, an engineered T-cell comprises (a) at least one chimeric antigen receptor (CAR); and (b) at least one genomic disruption of METRNL, CXCR6 and/or CXCL16. In certain embodiments, the genomic disruption is performed using a CRSIPR endonuclease system.
An engineered T-cell comprising disruption in an endogenous Meteorin-Like (METRNL) gene sequence.
An engineered T-cell comprising (a) at least one chimeric antigen receptor (CAR);
A method for treating cancer in a patient comprising the step of administering to the patient an effective amount of a METRNL inhibitor.
A method for treating an autoimmune disorder in a patient comprising the step of administering to the patient an effective amount of a METRNL agonist.
An engineered T-cell comprising a disruption in an endogenous C-X-C Motif Chemokine Receptor 6 (CXCR6) gene sequence.
An engineered T-cell comprising (a) at least one chimeric antigen receptor (CAR);
A method for treating cancer in a patient comprising the step of administering to the patient an effective amount of a CXCR6 inhibitor.
A method for treating an autoimmune disorder in a patient comprising the step of administering to the patient an effective amount of a CXCR6 agonist.
An engineered T-cell comprising a disruption in an endogenous C-X-C Motif Ligand 16 (CXCL16) gene sequence.
An engineered T-cell comprising (a) at least one chimeric antigen receptor (CAR);
A method for treating cancer in a patient comprising the step of administering to the patient an effective amount of a CXCL16 inhibitor.
A method for treating an autoimmune disorder in a patient comprising the step of administering to the patient an effective amount of a CXCL16 agonist.
Dependencies are inferred from the claim text.